Artios Pharma is new, exciting, dynamic Biotech company with a world class research team based south of Cambridge, UK.  Artios is focused on identifying and developing cancer treatments byexploiting novel targets within the DNA damage response (DDR), a scientific area of high expectation following the success of PARP inhibitors in the clinic.  The company is actively building an exciting portfolio of unique DNA repair projects.

Working with its collaborators, Artios has set out to identify and exploit novel protein classes across DDR pathways. We have in-licensed two lead programmes from Cancer Research Technology which target proteins that control key aspects of DNA repair and other cellular processes. Mechanistically, these programmes have the ability to kill cancer cells as single agents, or to sensitise cancer cells to radiotherapy and other DNA-damaging agents, including novel treatments, such as PARP inhibitors or immunotherapies.